The authors noted increased influx of immune cells into the tumor and tumor regression upon oncogenic inactivation, and identified BRAF and MYC as key mediators of KRAS-induced immune evasion (Ischenko et al., 2021). This evidence concerns the gene KRAS and neoplasm.